• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

E-132 Successful mechanical thrombectomy in an 11-year-old patient with emergent large vessel occlusion acute ischemic stroke related to congenital complete heart block and recent covid-19 infection
ConclusionsThis is a first known report of a successful mechanical thrombectomy in a pediatric patient due to a large vessel occlusion related to congenital complete heart block and recent COVID-19 infection.Disclosures J. Ansari: None. D. Mata Canadas: None. M. Ayub: None. J. Caskey: None. P. Simoncini: None. R. Riel-Romero: None. P. Sharma: None. D. Jordan: None. H. Cuellar: None.
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Ansari, J., Mata Canadas, D., Ayub, M., Caskey, J., Simoncini, P., Riel-Romero, R., Sharma, P., Jordan, D., Cuellar, H. Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research

Ischemic Stroke Due to Heparin-induced Thrombocytopenia During Severe COVID-19 Infection
Intern Med. 2022 Jul 5. doi: 10.2169/internalmedicine.9531-22. Online ahead of print.ABSTRACTA 53-year-old woman with severe coronavirus disease 2019 (COVID-19) pneumonia was admitted and treated with intravenous unfractionated heparin for thromboprophylaxis under general anesthesia with mechanical ventilation. She developed right hemiparesis after hospitalization due to a large hemorrhagic infarction. Her platelet count decreased from 243,000/μL at administration to 121,000/μL. Anti-platelet factor 4-heparin antibody testing was positive according to a latex immunoturbidimetric assay. She was therefore diagnosed with he...
Source: Internal Medicine - July 6, 2022 Category: Internal Medicine Authors: Yasutaka Murakami Shuhei Okazaki Makoto Yamamoto Rei Sakurai Jyunki Jinno Tatsuhiko Ozono Kensuke Ikenaka Yasufumi Gon Kenichi Todo Tsutomu Sasaki Haruhiko Hirata Akinori Uchiyama Hideki Mochizuki Source Type: research

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news